<DOC>
	<DOC>NCT02604836</DOC>
	<brief_summary>This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.</brief_summary>
	<brief_title>A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women who had been receiving onceweekly alendronate or risedronate for treatment or prevention of postmenopausal osteoporosis for greater than or equal to (&gt;=) 3 months Inability to stand or sit upright for &gt;=60 minutes Hypersensitivity to bisphosphonates Inability to swallow a tablet whole Malignant disease diagnosed within previous 10 years (except resected basal cell cancer).</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>